骨髓恶性肿瘤中的血栓形成：从 CHIP 到 AML。
Thrombosis in Myeloid Malignancies: From CHIP to AML.
机构信息
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, 00133, Italy.
Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH44195, USA.
出版信息
Cardiovasc Hematol Disord Drug Targets. 2024;24(1):2-12. doi: 10.2174/011871529X307253240530060107.
The development of myeloid malignancies is a multi-step process starting from pre-malignant stages. Large-scale studies on clonal hematopoiesis of indeterminate potential (CHIP) identified this condition as a risk factor for developing hematologic malignancies, in particular myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In parallel, CHIP was found to confer an enhanced thrombotic risk, in particular for cardiovascular diseases. In a similar fashion, in recent years, alongside their life-threatening features, increasing attention has been drawn toward thrombotic complications in myeloid malignancies. Thus, the purpose of this review is to gather a growing body of evidence on incidence, pathogenesis and clinical impact of thrombosis in myeloid malignancies at every step of malignant progression, from CHIP to AML.
髓系恶性肿瘤的发生是一个多步骤的过程，始于前恶性阶段。对不确定潜能克隆性造血（CHIP）的大规模研究将这种情况确定为发生血液系统恶性肿瘤的危险因素，特别是骨髓增生异常综合征（MDS）和急性髓系白血病（AML）。同时，CHIP 被发现会增加血栓形成的风险，特别是心血管疾病的风险。同样，近年来，除了其危及生命的特征外，髓系恶性肿瘤的血栓并发症也引起了越来越多的关注。因此，本综述的目的是汇集越来越多的证据，说明从 CHIP 到 AML 的恶性进展过程中各个阶段的髓系恶性肿瘤的血栓形成的发生率、发病机制和临床影响。
Zotero 插件